Vascepa, a prescription medication containing the active ingredient icosapent ethyl, is used to treat patients with elevated triglyceride levels. When taken in conjunction with statins, a class of drugs commonly used to manage cholesterol levels, Vascepa can enhance the effectiveness of blood thinners in patients at high risk for cardiovascular events (1).

Research has shown that icosapent ethyl, the active ingredient in Vascepa, has anti-inflammatory properties and can inhibit thromboxane production, leading to a decrease in platelet aggregation (2). This reduction in platelet aggregation is a key factor in the antithrombotic effects of icosapent ethyl.

A study published in the New England Journal of Medicine found that patients with high triglyceride levels who took Vascepa had a 25% reduction in major adverse cardiovascular events, including non-fatal myocardial infarction, non-fatal stroke, and cardiac death, compared to those who took a placebo (3).

The mechanism by which Vascepa enhances blood thinners involves the inhibition of thromboxane production, which in turn, reduces platelet aggregation. Thromboxane is a chemical compound that promotes platelet aggregation and vasoconstriction. By reducing thromboxane production, Vascepa can help to prevent the formation of blood clots and reduce the risk of cardiovascular events (4).

The use of Vascepa in conjunction with blood thinners should be carefully monitored due to the risk of bleeding complications. DrugPatentWatch.com provides information on the patent status of Vascepa and its marketing status (5).

Sources:
1. https://www.druginformation.org/drugs/vascepa
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319649/
3. https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
4. https://www.sciencedirect.com/science/article/pii/S0002870318301112
5. https://drugpatentwatch.com/drug/vascepa